Holen Sie sich die Stockscreener-App
5.39
17.15%
0.79
Acelyrin Inc Aktie (SLRN) Neueste Nachrichten
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - StockTitan
Acelyrin Inc (SLRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Acadian Asset Management LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
In the Green: Acelyrin Inc (SLRN) Closes at 4.31, Up/Down -8.30 from Previous Day - The Dwinnex
Results from Acelyrin Inc (SLRN) show risk - US Post News
SLRN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Los Angeles Capital Management LLC Takes $693,000 Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance
Significant Acquisition by T. Rowe Price Investment Management i - GuruFocus.com
Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab - TipRanks
ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com
Acelyrin Inc (SLRN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of - The Bakersfield Californian
Acelyrin, Inc. (NASDAQ:SLRN) Receives $10.83 Average Target Price from Analysts - MarketBeat
How does Acelyrin Inc (SLRN) change from a tortoise to a hare? - SETE News
Is it possible to buy Acelyrin Inc(SLRN) shares at a good price now? - US Post News
Acelyrin Inc (SLRN)’s Market Momentum: Closing Strong at 4.78, Down -0.62 - The Dwinnex
Company’s Banking Stock: Dissecting a 18.77% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Financial Metrics Unveiled: Acelyrin Inc (SLRN)’s Key Ratios in the Spotlight - The Dwinnex
Stocks of Acelyrin Inc (SLRN) are poised to climb above their peers - SETE News
Was there any good news for Acelyrin Inc (SLRN) stock in the last session? - US Post News
ACELYRIN, INC. to Participate in Upcoming Investor Conferences - StockTitan
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024 - MSN
Acelyrin (NASDAQ:SLRN) Price Target Cut to $6.00 by Analysts at Morgan Stanley - Defense World
California State Teachers Retirement System Has $49,000 Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com India
Acelyrin (NASDAQ:SLRN) PT Lowered to $6.00 at Morgan Stanley - MarketBeat
Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com Canada
Closing Strong: Acelyrin Inc (SLRN) Ends at 4.13, Up 3.77 from Last Close - The Dwinnex
Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com UK
20,703 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Price T Rowe Associates Inc. MD - Defense World
Acelyrin (NASDAQ:SLRN) Stock Rating Lowered by HC Wainwright - Defense World
Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) Target Price at $12.00 - Defense World
Q3 2024 Earnings Forecast for Acelyrin, Inc. (NASDAQ:SLRN) Issued By HC Wainwright - MarketBeat
Q3 2024 Earnings Estimate for Acelyrin, Inc. (NASDAQ:SLRN) Issued By HC Wainwright - Defense World
Piper Sandler Lowers Acelyrin (NASDAQ:SLRN) Price Target to $20.00 - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Q2 2024 Earnings Call Transcript - Insider Monkey
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN - GuruFocus.com
TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com Australia
Acelyrin (NASDAQ:SLRN) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - Defense World
SLRN Stock Touches 52-Week Low at $3.6 Amid Market Challenges - Investing.com
Piper Sandler cuts Acelyrin stock target, maintains overweight rating - Investing.com
Acelyrin Belatedly Drops Izokibep In Its Lead Indications - Scrip
Acelyrin stock rating downgraded amid pipeline shift By Investing.com - Investing.com India
TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com India
Earnings call: Acelyrin outlines refocused pipeline and positive drug trials - Investing.com
Earnings call: Acelyrin outlines refocused pipeline and positive drug trials By Investing.com - Investing.com UK
Acelyrin stock rating downgraded amid pipeline shift By Investing.com - Investing.com Australia
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
HS dropout as math favors Acelyrin’s TED course with lonigutamab - BioWorld Online
Acelyrin (NASDAQ:SLRN) PT Lowered to $20.00 at Piper Sandler - MarketBeat
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity - BioCentury
Piper Sandler cuts Acelyrin stock target, maintains overweight rating By Investing.com - Investing.com Canada
ACELYRIN reports positive Phase 3 trial results for izokibe By Investing.com - Investing.com Australia
Acelyrin (NASDAQ:SLRN) Announces Earnings Results - MarketBeat
Acelyrin stock rating downgraded amid pipeline shift By Investing.com - Investing.com Canada
Citi cuts Acelyrin stock target on strategic shift - Investing.com
Citi cuts Acelyrin stock target on strategic shift By Investing.com - Investing.com Canada
SLRN Stock Touches 52-Week Low at $3.6 Amid Market Challenges - Investing.com Canada
Acelyrin stock rating downgraded amid pipeline shift - Investing.com
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep - Benzinga
TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com
TD Cowen retains Buy rating on Acelyrin stock, cites strong potential - Investing.com UK
Piper Sandler cuts Acelyrin stock target, maintains overweight rating - Investing.com India
Piper Sandler cuts Acelyrin stock target, maintains overweight rating By Investing.com - Investing.com Australia
ACELYRIN reports positive Phase 3 trial results for izokibe - Investing.com India
Citi cuts Acelyrin stock target on strategic shift - Investing.com India
1.13%
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):